---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-004358"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2025-04-03T23:59:59+00:00"
generated_at: "2026-05-23T22:44:16.434093+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences appoints Ron Philip to Board of Directors effective April 2, 2025

## Summary
- Ron Philip, age 51, appointed as Class III director filling vacancy from Jack Bech Nielsen's resignation.
- Philip will serve on the Audit Committee and Nominating and Corporate Governance Committee.
- He is current CEO of Orbital Therapeutics and former CEO of Spark Therapeutics (April 2022–September 2024).
- Philip has 30 years of biotech experience including roles at Pfizer, Wyeth, and Merck.
- Board determined Philip qualifies as independent under Nasdaq standards; standard director compensation applies.

## SEC filing metadata
- accession: 0001558370-25-004358
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2025-04-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000155837025004358/0001558370-25-004358-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000155837025004358/hrmy-20250402x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-004358
- JSON: https://secwatch.observer/filing/0001558370-25-004358.json
- Plain text: https://secwatch.observer/filing/0001558370-25-004358.txt

## Key facts
- Executive change
  Ron Philip was appointed as Class III director at Harmony Biosciences Holdings, Inc..
  - Action: appointed
  - Role: Class III director
  source text: Effective April 2, 2025, the Board of Directors (the “Board”) of Harmony Biosciences Holdings, Inc. (the “Company”) appointed Ron Philip, age 51, as a Class III director, filling the previously announced vacancy in the Board created by the resignation of Jack Bech Nielsen effective June 27, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000155837025004358/0001558370-25-004358-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.